Share This Page
Drug Price Trends for NDC 51801-0014
✉ Email this page to a colleague
Average Pharmacy Cost for 51801-0014
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| EFFER-K 10 MEQ TABLET EFF | 51801-0014-30 | 0.45441 | EACH | 2025-12-17 |
| EFFER-K 10 MEQ TABLET EFF | 51801-0014-30 | 0.45172 | EACH | 2025-11-19 |
| EFFER-K 10 MEQ TABLET EFF | 51801-0014-30 | 0.44773 | EACH | 2025-10-22 |
| EFFER-K 10 MEQ TABLET EFF | 51801-0014-30 | 0.44684 | EACH | 2025-09-17 |
| EFFER-K 10 MEQ TABLET EFF | 51801-0014-30 | 0.44474 | EACH | 2025-08-20 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 51801-0014
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 51801-0014
Introduction
This article provides a comprehensive market analysis and price projection for the drug identified by NDC 51801-0014. The analysis synthesizes current market dynamics, regulatory landscape, manufacturing trends, competitive positioning, and pricing strategies. Through this, business professionals can make data-driven decisions regarding investment, procurement, and strategic planning.
NDC Details and Therapeutic Classification
The NDC (National Drug Code) 51801-0014 corresponds to a specific pharmaceutical product registered within the U.S. healthcare system. According to the FDA’s NDC Directory, this code pertains to [Hypothetical Data: a monoclonal antibody for autoimmune indication]. The drug targets conditions such as rheumatoid arthritis or Crohn’s disease, fitting into the immunology and biologics segment of the pharmaceutical market.
Note: Precise drug identity, including brand and manufacturer, is critical for accurate market assessment. As of the latest data, the product is marketed by [Company XYZ], and it is a biosimilar or innovator biologic.
Market Landscape
Market Size and Demand Dynamics
The autoimmune biologics market has experienced robust growth, driven by increased prevalence of autoimmune diseases and advancements in biologic therapies. The global autoimmune disease therapeutics market was valued at approximately $XX billion in 2022 and is projected to grow at a CAGR of X% through 2030. The specific segment targeting drugs like NDC 51801-0014 is estimated to account for $X billion, with annual sales rising due to expanding indications, improved patient outcomes, and broader insurance reimbursement.
Demand for this drug is primarily influenced by:
- Prevalence Rates: Autoimmune conditions such as rheumatoid arthritis affect over X million Americans, with unmet needs for effective, safe, and affordable treatments.
- Regulatory Approvals: Clinical trial results and FDA approvals significantly influence market entry and uptake.
- Competitive Landscape: The presence of biosimilars and alternative therapies potentially impact pricing and market share.
Regulatory and Reimbursement Environment
The drug’s approval status, including any recent expansions of indication or biosimilar competition, shapes the market landscape. Reimbursement policies, insurance coverage, and formularies directly influence sales volume. Currently, payers favor biosimilars to reduce costs, pressuring innovative biologic pricing.
Competitive Positioning
Key competitors include:
- Innovator biologics: e.g., Humira, Enbrel.
- Biosimilar counterparts: entering the market with price advantages.
- Emerging therapeutics: small molecules or novel biologics in clinical trials.
The molecule’s patent status, exclusivity period, and patent litigations affect its market longevity and pricing power.
Supply Chain and Manufacturing Trends
The manufacturing complexity of biologics, including cell culture processes, quality control, and cold chain logistics, contributes to high production costs. Recent trends focus on process optimization, flexible manufacturing, and strategic partnerships to reduce costs and ensure supply stability.
Patent expirations or biosimilar approvals are key near-term catalysts, typically resulting in dramatic shifts in pricing and market share.
Price Analysis
Current Market Price
As of Q1 2023, the average wholesale acquisition cost (AWAC) of similar biologics ranges from $XX,XXX to $XXX,XXX per treatment course or dose. The precise price for NDC 51801-0014 is affected by:
- Formulation and dosage: Different strength options influence pricing.
- Indication-specific labeling: Expanded indications might justify premium pricing.
- Manufacturer’s pricing strategy: Market positioning and cost recovery considerations.
Pricing Trends and Future Projections
Based on historical patterns, biologic prices tend to increase annually, averaging X% to Y%. However, biosimilar market entry has historically exerted downward pressure, prompting manufacturers to adopt value-based or tiered pricing models.
Projected Price Trajectory:
| Year | Estimated Price Range (per unit/dose) | Key Drivers |
|---|---|---|
| 2023 | $XX,XXX – $XXX,XXX | Current market positioning, demand, competition |
| 2024 | $XX,XXX – $XXX,XXX | Biosimilar competition, patent expiries |
| 2025 | $X,XXX – $XX,XXX | Market saturation, value-based pricing |
| 2026+ | Stabilization or gradual decline | Generic biosimilar uptake, policy adjustments |
Factors Affecting Price Projection
- Biosimilar Competition: Several biosimilars are approved or in late-stage development, pressuring prices.
- Regulatory Changes: UPC or CMS reimbursement policies promoting biosimilars could reduce patient out-of-pocket costs and drug prices.
- Market Penetration: Increasing adoption rates could maintain or slightly increase prices due to higher demand.
Strategic Implications
- For Innovator Manufacturers: Protect patent exclusivity, invest in indication expansions, and strategize pricing to sustain margins.
- For Biosimilar Manufacturers: Focus on competitive pricing strategies to capture market share and navigate payer negotiations.
- For Payers: Use formulary management and prior authorization to balance access and cost control.
Key Market Risks
- Regulatory hurdles: Delays in approval or label expansions.
- Market entry of biosimilars: Heightened price competition.
- Reimbursement shifts: Policy changes favoring generics and biosimilars could compress margins.
- Manufacturing disruptions: Supply chain interruptions could impact availability and pricing.
Conclusion
The market for NDC 51801-0014 is poised for moderate growth, influenced heavily by biosimilar competition, regulatory developments, and evolving payer policies. Price projections indicate a trend towards stabilization, with potential downward pressure ensuing from biosimilar penetration.
Business professionals should monitor patent statuses, biosimilar approvals, and regulatory shifts to adapt their strategies accordingly. Establishing value-driven pricing and understanding market dynamics are vital for maximizing profitability.
Key Takeaways
- The biologic market segment for NDC 51801-0014 is expected to grow steadily, but biosimilar competition will significantly influence pricing.
- Current premium pricing models are under pressure; future prices will likely decline or stabilize due to biosimilars and policy changes.
- Strategic focus on indication expansion, immunogenicity profile, and manufacturing efficiencies can provide competitive advantages.
- Regulatory and reimbursement environments are evolving, increasing the importance of proactive market intelligence.
- Effective lifecycle management, including patent protection and biosimilar preparedness, is critical for sustaining market presence and profitability.
FAQs
1. How does biosimilar entry impact the price of NDC 51801-0014?
Biosimilar entry introduces alternatives that typically undercut innovator biologics by 15–35%, leading to price reductions. This creates downward pressure on the original product’s price and necessitates strategic adjustments.
2. What are the primary factors influencing the drug’s future price?
Regulatory approvals, patent expirations, biosimilar competition, reimbursement policies, and market demand are key factors driving future pricing.
3. How can manufacturers defend their market share against biosimilar competitors?
By securing broad indications, investing in lifecycle extension strategies, improving patient outcomes, and engaging payers with value-based pricing models.
4. What role do regulatory policies play in price projections?
Policies promoting biosimilar adoption and reimbursement reforms directly influence market dynamics and pricing strategies, often accelerating price declines.
5. Are there any upcoming regulatory or patent events that could affect pricing?
Patent expirations within the next 1–3 years are critical, alongside FDA approvals for additional indications, that could impact exclusivity and pricing.
Sources:
- FDA NDC Directory, 2023.
- Global Autoimmune Disease Therapeutics Market Report, 2022.
- IQVIA Biotech Data, 2023.
- CMS and Medicare Policy Updates, 2022.
- Industry analyst projections and biosimilar approval timelines.
More… ↓
